Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Graves' disease after treatment with Alemtuzumab for multiple sclerosis.
In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the CNS.
Comparing routine neurorehabilitation program with trunk exercises based on Bobath concept in multiple sclerosis: Pilot study.
Can smoking aggravate my multiple sclerosis symptoms?
Alemtuzumab 3-year data show durable effect on MS disability
Inhibition of autoimmune encephalomyelitis by a tetracycline.
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
[Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal.]
Presumptive Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis after Natalizumab Therapy.
MULTIPLE SCLEROSIS: MOLECULAR MECHANISMS AND THERAPEUTIC OPPORTUNITIES.
Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk.
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
Riluzole enhances glutamate uptake in rat astrocyte cultures.
Historical Issues of Optic neuritis and Sensory Disorder in Persian Traditional Medicine.
Personalized Medicine in Neurodegenerative Diseases: How Far Away?
CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.
Neurorehabilitation for other neurologic disorders.
Spinal Cord Atrophy and Early Motor Recovery following Transverse Myelitis in Pediatric Patients.
Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels.
CD44 is required for the migration of transplanted oligodendrocyte progenitor cells to focal inflammatory demyelinating lesions in the spinal cord.
Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis - a multicentre cohort study.
In Active Relapsing-Remitting Multiple Sclerosis, Effector T Cell Resistance to Adaptive Tregs Involves IL-6-Mediated Signaling.
Immunological Hallmarks of JC Virus Replication in Multiple Sclerosis Patients on Long-Term Natalizumab.
Progressive multifocal leukoencephalopathy: new concepts.

Pages